Literature DB >> 22511463

3-T proton magnetic spectroscopy in unmedicated first episode psychosis: a focus on creatine.

Philip G Tibbo1, Denise Bernier, Christopher C Hanstock, Peter Seres, Bonnie Lakusta, Scot E Purdon.   

Abstract

Different lines of evidence suggest an abnormal cerebral energy metabolism as being critical to the pathophysiology of schizophrenia. However, it is unknown as to whether levels of creatine (Cr) would be involved in these anomalies. The study involved 33 unmedicated first episode psychosis patients and 41 healthy controls. Proton magnetic resonance spectroscopy ((1) H-MRS) was performed at 3 T using a long TE (TE/TM/TR of 240/27/3000 ms) such that within the total phosphocreatine (PCr) plus Cr signal (tCr(240)), mainly Cr was detectable. The target region was an 18 cm(3) prefrontal volume. A negative association was found between age of patients and tCr(240) levels referenced to internal water, with 20% of the variance in tCr(240) accounted for by Age. A secondary finding revealed 16% reduction of tCr(240) levels in patients, solely when comparing participants older than the median age of patients. No association existed between tCr(240) levels and clinical variables. These findings support previous data reporting abnormalities in brain creatine kinase isoenzymes involved with the maintenance of energy pools in schizophrenia. The implications of using a long TE are discussed in terms of the relative proportions of Cr and PCr within the tCr(240) signal, and of potential group differences in T(2) times.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22511463     DOI: 10.1002/mrm.24291

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  14 in total

Review 1.  A review of altered biochemistry in the anterior cingulate cortex of first-episode psychosis.

Authors:  L Squarcina; J A Stanley; M Bellani; C A Altamura; P Brambilla
Journal:  Epidemiol Psychiatr Sci       Date:  2017-01-20       Impact factor: 6.892

2.  Prefrontal and Striatal Gamma-Aminobutyric Acid Levels and the Effect of Antipsychotic Treatment in First-Episode Psychosis Patients.

Authors:  Camilo de la Fuente-Sandoval; Francisco Reyes-Madrigal; Xiangling Mao; Pablo León-Ortiz; Oscar Rodríguez-Mayoral; Helgi Jung-Cook; Rodolfo Solís-Vivanco; Ariel Graff-Guerrero; Dikoma C Shungu
Journal:  Biol Psychiatry       Date:  2017-10-10       Impact factor: 13.382

3.  Relationship of auditory electrophysiological responses to magnetic resonance spectroscopy metabolites in Early Phase Psychosis.

Authors:  Lisa A Bartolomeo; Andrew M Wright; Ruoyun E Ma; Tom A Hummer; Michael M Francis; Andrew C Visco; Nicole F Mehdiyoun; Amanda R Bolbecker; William P Hetrick; Ulrike Dydak; John Barnard; Brian F O'Donnell; Alan Breier
Journal:  Int J Psychophysiol       Date:  2019-05-23       Impact factor: 2.997

4.  Glutamatergic Response to Heat Pain Stress in Schizophrenia.

Authors:  Joshua Chiappelli; Qiaoyun Shi; Sarah Andrea Wijtenburg; Raimi Quiton; Krista Wisner; Frank Gaston; Priyadurga Kodi; Christopher Gaudiot; Peter Kochunov; Laura M Rowland; Liyi Elliot Hong
Journal:  Schizophr Bull       Date:  2018-06-06       Impact factor: 9.306

5.  Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia.

Authors:  Nina V Kraguljac; David M White; Meredith A Reid; Adrienne C Lahti
Journal:  JAMA Psychiatry       Date:  2013-12       Impact factor: 21.596

6.  Heritability of cerebral glutamate levels and their association with schizophrenia spectrum disorders: a 1[H]-spectroscopy twin study.

Authors:  Christian Stefan Legind; Brian Villumsen Broberg; René Christiaan William Mandl; Rachel Brouwer; Simon Jesper Anhøj; Rikke Hilker; Maria Høj Jensen; Philip McGuire; Hilleke Hulshoff Pol; Birgitte Fagerlund; Egill Rostrup; Birte Yding Glenthøj
Journal:  Neuropsychopharmacology       Date:  2018-10-09       Impact factor: 7.853

7.  Reduced GABA/glutamate in the thalamus of individuals at clinical high risk for psychosis.

Authors:  Gonzalo M Quiñones; Ahmad Mayeli; Victor E Yushmanov; Hoby P Hetherington; Fabio Ferrarelli
Journal:  Neuropsychopharmacology       Date:  2020-12-03       Impact factor: 7.853

Review 8.  Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies.

Authors:  Tomomi Nakahara; Sakiko Tsugawa; Yoshihiro Noda; Fumihiko Ueno; Shiori Honda; Megumi Kinjo; Hikari Segawa; Nobuaki Hondo; Yukino Mori; Honoka Watanabe; Kazuho Nakahara; Kazunari Yoshida; Masataka Wada; Ryosuke Tarumi; Yusuke Iwata; Eric Plitman; Sho Moriguchi; Camilo de la Fuente-Sandoval; Hiroyuki Uchida; Masaru Mimura; Ariel Graff-Guerrero; Shinichiro Nakajima
Journal:  Mol Psychiatry       Date:  2021-09-28       Impact factor: 15.992

9.  A multimodal approach to studying the relationship between peripheral glutathione, brain glutamate, and cognition in health and in schizophrenia.

Authors:  Kun Yang; Anouk Marsman; Subechhya Pradhan; Jennifer M Coughlin; Min Wang; Rebecca E Ward; Susanne Bonekamp; Emily B Ambinder; Cecilia P Higgs; Pearl K Kim; Jamie A Edwards; Mark Varvaris; Hongxing Wang; Sotirios Posporelis; Shuangchao Ma; Tsuyoshi Tsujimura; Richard A E Edden; Martin G Pomper; Thomas W Sedlak; Margot Fournier; David J Schretlen; Nicola G Cascella; Peter B Barker; Akira Sawa
Journal:  Mol Psychiatry       Date:  2020-10-19       Impact factor: 15.992

10.  Medial Prefrontal Cortex Glutamate Is Reduced in Schizophrenia and Moderated by Measurement Quality: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies.

Authors:  Jason Smucny; Cameron S Carter; Richard J Maddock
Journal:  Biol Psychiatry       Date:  2021-06-12       Impact factor: 12.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.